Attitude of Swiss physicians towards opioid-induced constipation: A national survey

European Journal of Internal Medicine

Volumn 22, Issue 5, 2011, Pages 527-531

  Hess, Bernhard ^a   Bernardi, Marco ^a   Klotz, Hans Peter ^a  

^a KLINIK IM PARK   (Switzerland)

Author keywords

Chronic pain; Combined opioid receptor agonist and antagonist; Opioid therapy; Opioid induced constipation; Swiss national survey

Indexed keywords

OPIATE;

ANOREXIA; CONSTIPATION; CONVULSION; DRUG COST; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; EPIGASTRIC FULLNESS; FLATULENCE; HEALTH SURVEY; HUMAN; OPIATE INDUCED CONSTIPATION; PAIN; PATIENT COMPLIANCE; PHYSICIAN ATTITUDE; PREVALENCE; REVIEW; SWITZERLAND; TREATMENT DURATION;

EID: 80052969416     PISSN: 09536205     EISSN: 18790828     Source Type: Journal    
DOI: 10.1016/j.ejim.2011.02.014     Document Type: Article

References (21)

1. S.J. Panchal, P. Muller-Schwefe, and J.I. Wurzelmann Opioid-induced bowel dysfunction: prevalence, pathophysiology and burden Int J Clin Pract 61 2007 1181 1187 (Pubitemid 46934629)
2. M. Pappagallo Incidence, prevalence, and management of opioid bowel dysfunction Am J Surg 182 2001 11S 18S (Pubitemid 34072942)
3. G.F. Longstreth, W.G. Thompson, W.D. Chey, L.A. Houghton, F. Mearin, and R.C. Spiller Functional bowel disorders Gastroenterology 130 2006 1480 1491
4. T.J. Bell, S.J. Panchal, C. Miaskowski, S.C. Bolge, T. Milanova, and R. Williamson The prevalence, severity, and impact of opioid-induced bowel dysfunction: results of a US and European Patient Survey (PROBE 1) Pain Med 10 2009 35 42
5. S.C. McMillan Assessing and managing opiate-induced constipation in adults with cancer Cancer Control 11 2004 3 9 (Pubitemid 38756665)
6. E. McNicol, N. Horowicz-Mehler, R.A. Fisk, K. Bennett, M. Gialeli-Goudas, and P.W. Chew Management of opioid side effects in cancer-related and chronic noncancer pain: a systematic review J Pain 4 2003 231 256 (Pubitemid 36807905)
7. A. Kurz, and D.I. Sessler Opioid-induced bowel dysfunction: pathophysiology and potential new therapies Drugs 63 2003 649 671 (Pubitemid 36408072)
8. Rome Foundation Diagnostic Criteria for Functional Gastrointestinal Disorders (Appendix A) D.A. Drossman, E. Corazziari, M. Delvaux, R.C. Spiller, N.J. Talley, W.G. Thompson, Rome III: The Functional Gastrointestinal Disorders Third Edition 2006 VA: Degnon Associates, Inc McLean 885 898 http://www.romecriteria.org/assets/pdf/19-RomeIII-apA-885-898.pdf
9. J.M. Swegle, and C. Logemann Management of common opioid-induced adverse effects Am Fam Physician 74 2006 1347 1354 (Pubitemid 44607306)
10. A. De Luca, and I.M. Coupar Insights into opioid action in the intestinal tract Pharmacol Ther 69 1996 103 115 (Pubitemid 26111425)
11. H.U. De Schepper, F. Cremonini, M.I. Park, and M. Camilleri Opioids and the gut: pharmacology and current clinical experience Neurogastroenterol Motil 16 2004 383 394 (Pubitemid 39140632)
12. P. Holzer Opioids and opioid receptors in the enteric nervous system: from a problem in opioid analgesia to a possible new prokinetic therapy in humans Neurosci Lett 361 2004 192 195 (Pubitemid 38609249)
13. J.E. Shook, J.T. Pelton, V.J. Hruby, and T.F. Burks Peptide opioid antagonist separates peripheral and central opioid antitransit effects J Pharmacol Exp Ther 243 1987 492 500 (Pubitemid 18011529)
14. K. Smith, M. Hopp, G. Mundin, P. Leyendecker, P. Bailey, and B. Grothe Single- and multiple-dose pharmacokinetic evaluation of oxycodone and naloxone in an opioid agonist/antagonist prolonged-release combination in healthy adult volunteers Clin Ther 30 2008 2051 2068
15. J.C. Gorski, D.R. Jones, S.A. Wrighton, and S.D. Hall Characterization of dextromethorphan N-demethylation by human liver microsomes. Contribution of the cytochrome P4503A (CYP3A) subfamily Biochem Pharmacol 48 1994 173 182
16. B. Lalovic, B. Phillips, L.L. Risler, W. Howald, and D.D. Shen Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes Drug Metab Dispos 32 2004 447 454 (Pubitemid 38420280)
17. Y.S. Choi, and J.A. Billings Opioid antagonists: a review of their role in palliative care, focusing on use in opioid-related constipation J Pain Symptom Manage 24 2002 71 90
18. W. Meissner, P. Leyendecker, S. Mueller-Lissner, J. Nadstawek, M. Hopp, and C. Ruckes A randomised controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipation Eur J Pain 13 2009 56 64
19. K. Simpson, P. Leyendecker, M. Hopp, S. Müller-Lissner, O. Löwenstein, and J. De Andres Fixed-ratio combination oxycodone/naloxone compared with oxycodone alone for the relief of opioid-induced constipation in moderate-to-severe noncancer pain Curr Med Res Opin 24 2008 3503 3512
20. D. Vondrackova, P. Leyendecker, W. Meissner, M. Hopp, I. Szombati, and K. Hermanns Analgesic efficacy and safety of oxycodone in combination with naloxone as prolonged release tablets in patients with moderate to severe chronic pain J Pain 9 2008 1144 1154
21. O. Löwenstein, P. Leyendecker, M. Hopp, U. Schutter, P.D. Rogers, and R. Uhl Combined prolonged-release oxycodone and naloxone improves bowel function in patients receiving opioids for moderate-to-severe non-malignant chronic pain: a randomised controlled trial Expert Opin Pharmacother 10 2009 531 543